Immuneering Corporation
IMRX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.44 | 0.03 | -0.05 | -0.30 |
| FCF Yield | -7.79% | -26.09% | -21.26% | -18.14% |
| EV / EBITDA | -6.74 | -1.44 | -1.97 | -2.20 |
| Quality | ||||
| ROIC | -44.31% | -33.46% | -40.44% | -24.52% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.80 | 0.65 | 0.94 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 32.94% | 2.96% | -7.74% | -16.60% |
| Safety | ||||
| Net Debt / EBITDA | 1.52 | 2.06 | 1.73 | 2.70 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,347.11 | -671.31 | 0.00 | -995.48 |